Pharmacological basis for the neurocognitive effect of atypical antipsychotic drugs

Toshihide Kuroki, Tatsuo Nakahara

Research output: Contribution to journalReview article

Abstract

Cognitive impairment is a key feature of schizophrenia and may be the most important determinant of outcome in schizophrenia. Certain kinds of atypical antipsychotic drugs (APDs) have been reported to improve cognitive symptoms of schizophrenia, although little is known about the mechanism of this action. The aim of this paper is to consider the pharmacological basis for the superior efficacy of atypical APDs on cognitive function. In animal studies, atypical APDs have demonstrated to modulate dopamine (DA) and acetylcholine (Ach) neurotransmission preferentially in the cortical areas. Atypical APDs, unlike typical APDs, increase DA release in the prefrontal cortex to a greater extent than in the subcortical regions such as the striatum and nucleus accumbens, as measured by in vivo microdialysis. This preferential effect of atypical APDs may be related to their common receptor binding profiles such as greater affinities to serotonin (5-HT)2A receptors than DA-D2 receptors, in addition with significant ability to stimulate 5-HT1A receptors. Atypical APDs, but not typical APDs, also induce Ach release in the prefrontal cortex and hippocampus. Despite antagonism by some atypical APDs to muscarinic Ach receptors, these drugs may counteract it with an increase in Ach release. Thus, the greater ability of atypical APDs than typical APDs to enhance the release of DA and Ach in the cortical regions may be related to the neurocognitive effect of atypical APDs that are thought to ameliorate the hypofrontality responsible for cognitive deficits of schizophrenia. Copyright

Original languageEnglish
Pages (from-to)10-20
Number of pages11
JournalClinical Psychopharmacology and Neuroscience
Volume8
Issue number1
Publication statusPublished - Apr 1 2010

Fingerprint

Antipsychotic Agents
Pharmacology
Acetylcholine
Schizophrenia
Dopamine
Aptitude
Prefrontal Cortex
Receptor, Serotonin, 5-HT2A
Neurobehavioral Manifestations
Receptor, Serotonin, 5-HT1A
Dopamine D2 Receptors
Microdialysis
Nucleus Accumbens
Muscarinic Receptors
Synaptic Transmission
Cognition
Hippocampus
Serotonin

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Pharmacology (medical)

Cite this

Pharmacological basis for the neurocognitive effect of atypical antipsychotic drugs. / Kuroki, Toshihide; Nakahara, Tatsuo.

In: Clinical Psychopharmacology and Neuroscience, Vol. 8, No. 1, 01.04.2010, p. 10-20.

Research output: Contribution to journalReview article

@article{355beb6afaa74594b463eeeb7de449c7,
title = "Pharmacological basis for the neurocognitive effect of atypical antipsychotic drugs",
abstract = "Cognitive impairment is a key feature of schizophrenia and may be the most important determinant of outcome in schizophrenia. Certain kinds of atypical antipsychotic drugs (APDs) have been reported to improve cognitive symptoms of schizophrenia, although little is known about the mechanism of this action. The aim of this paper is to consider the pharmacological basis for the superior efficacy of atypical APDs on cognitive function. In animal studies, atypical APDs have demonstrated to modulate dopamine (DA) and acetylcholine (Ach) neurotransmission preferentially in the cortical areas. Atypical APDs, unlike typical APDs, increase DA release in the prefrontal cortex to a greater extent than in the subcortical regions such as the striatum and nucleus accumbens, as measured by in vivo microdialysis. This preferential effect of atypical APDs may be related to their common receptor binding profiles such as greater affinities to serotonin (5-HT)2A receptors than DA-D2 receptors, in addition with significant ability to stimulate 5-HT1A receptors. Atypical APDs, but not typical APDs, also induce Ach release in the prefrontal cortex and hippocampus. Despite antagonism by some atypical APDs to muscarinic Ach receptors, these drugs may counteract it with an increase in Ach release. Thus, the greater ability of atypical APDs than typical APDs to enhance the release of DA and Ach in the cortical regions may be related to the neurocognitive effect of atypical APDs that are thought to ameliorate the hypofrontality responsible for cognitive deficits of schizophrenia. Copyright",
author = "Toshihide Kuroki and Tatsuo Nakahara",
year = "2010",
month = "4",
day = "1",
language = "English",
volume = "8",
pages = "10--20",
journal = "Clinical Psychopharmacology and Neuroscience",
issn = "1738-1088",
publisher = "Korean College of Neuropsychopharmacology",
number = "1",

}

TY - JOUR

T1 - Pharmacological basis for the neurocognitive effect of atypical antipsychotic drugs

AU - Kuroki, Toshihide

AU - Nakahara, Tatsuo

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Cognitive impairment is a key feature of schizophrenia and may be the most important determinant of outcome in schizophrenia. Certain kinds of atypical antipsychotic drugs (APDs) have been reported to improve cognitive symptoms of schizophrenia, although little is known about the mechanism of this action. The aim of this paper is to consider the pharmacological basis for the superior efficacy of atypical APDs on cognitive function. In animal studies, atypical APDs have demonstrated to modulate dopamine (DA) and acetylcholine (Ach) neurotransmission preferentially in the cortical areas. Atypical APDs, unlike typical APDs, increase DA release in the prefrontal cortex to a greater extent than in the subcortical regions such as the striatum and nucleus accumbens, as measured by in vivo microdialysis. This preferential effect of atypical APDs may be related to their common receptor binding profiles such as greater affinities to serotonin (5-HT)2A receptors than DA-D2 receptors, in addition with significant ability to stimulate 5-HT1A receptors. Atypical APDs, but not typical APDs, also induce Ach release in the prefrontal cortex and hippocampus. Despite antagonism by some atypical APDs to muscarinic Ach receptors, these drugs may counteract it with an increase in Ach release. Thus, the greater ability of atypical APDs than typical APDs to enhance the release of DA and Ach in the cortical regions may be related to the neurocognitive effect of atypical APDs that are thought to ameliorate the hypofrontality responsible for cognitive deficits of schizophrenia. Copyright

AB - Cognitive impairment is a key feature of schizophrenia and may be the most important determinant of outcome in schizophrenia. Certain kinds of atypical antipsychotic drugs (APDs) have been reported to improve cognitive symptoms of schizophrenia, although little is known about the mechanism of this action. The aim of this paper is to consider the pharmacological basis for the superior efficacy of atypical APDs on cognitive function. In animal studies, atypical APDs have demonstrated to modulate dopamine (DA) and acetylcholine (Ach) neurotransmission preferentially in the cortical areas. Atypical APDs, unlike typical APDs, increase DA release in the prefrontal cortex to a greater extent than in the subcortical regions such as the striatum and nucleus accumbens, as measured by in vivo microdialysis. This preferential effect of atypical APDs may be related to their common receptor binding profiles such as greater affinities to serotonin (5-HT)2A receptors than DA-D2 receptors, in addition with significant ability to stimulate 5-HT1A receptors. Atypical APDs, but not typical APDs, also induce Ach release in the prefrontal cortex and hippocampus. Despite antagonism by some atypical APDs to muscarinic Ach receptors, these drugs may counteract it with an increase in Ach release. Thus, the greater ability of atypical APDs than typical APDs to enhance the release of DA and Ach in the cortical regions may be related to the neurocognitive effect of atypical APDs that are thought to ameliorate the hypofrontality responsible for cognitive deficits of schizophrenia. Copyright

UR - http://www.scopus.com/inward/record.url?scp=77952088250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952088250&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77952088250

VL - 8

SP - 10

EP - 20

JO - Clinical Psychopharmacology and Neuroscience

JF - Clinical Psychopharmacology and Neuroscience

SN - 1738-1088

IS - 1

ER -